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1516these recommendations. Therefore, many are based on
expert consensus. As the procedures evolve, technology
changes, experience grows, and more data accumulate,
there will certainly be a need to update these recom-
mendations. However, with the FDA having just approved
these devices, the writing committee and participating
societies believe that the recommendations listed in this
report serve as an appropriate starting point. Since there
is a strong consensus that these new valve therapies are
best performed using a team approach, these credential-
ing criteria may be best applied at the institutional level.
Partnering societies used the ACC’s policy on relation-
ships with industry to author this document (1). To avoid
actual, potential, or perceived conﬂicts of interest that
could arise as a result of industry relationships
with or personal interests of the writing committee, all
members of the writing committee, as well as peer
reviewers of the document, were asked to disclose all
current healthcare-related relationships, including those
existing 12 months before initiation of the writing effort. A
committee of interventional cardiologists and surgeons
was formed to include a majority of members with no rel-
evant relationships with industry (RWI) or other entities,
and was led by an interventional cardiology chair and a
surgical co-chair with no relevant RWI. Authors with rel-
evant RWIwere not permitted to draft or vote on content or
recommendations pertaining to their RWI. RWI were
reviewed on all conference calls and updated as changes
occurred. Author and peer reviewer RWI pertinent to this
document are disclosed in Appendices A and B, respec-
tively. In addition, to ensure complete transparency,
authors’ comprehensive disclosure information (including
RWI not pertinent to this document) is available as an
online supplement to this document. The work of the
writing committee was supported exclusively by the
partnering societies without commercial support. Writing
committee members volunteered their time for this
effort. Conference calls of the writing committee were
conﬁdential and attended only by committee members.
SCAI, AATS, ACC, and STS believe that adherence to
these recommendations will maximize the chances that
these therapies will become a successful part of the
armamentarium for treating valvular heart disease in the
United States. In addition, these recommendations willBolman RM, Miller DC, Moon MR, Trento A, Aldea GS, Bacha EA. SCAI/AATS/
ACC/STS operator and institutional requirements for transcatheter valve repair
and replacement. Part II. Mitral valve. J Am Coll Cardiol 2014;64:1515–26.
This article is copublished in Catheterization and Cardiovascular Interventions,
the Annals of Thoracic Surgery, and the Journal of Thoracic and Cardiovascular
Surgery.
Copies: This document is available on the World Wide Web sites of the Society
for Cardiovascular Angiography and Interventions (www.scai.org),
the American Association for Thoracic Surgery (www.aats.org), the Americanhopefully facilitate optimum quality during the delivery
of this therapy, which will be important to the develop-
ment and implementation of future, less invasive
approaches to structural heart disease.
INTRODUCTION
Fueled by the development of new technologies, treatment
of valvular heart disease by transcatheter techniques has
become part of the armamentarium of cardiac providers,
enabling less invasive treatment for patients previously
treatable only with open-heart surgery or, in many cases,
not treatable at all. Recognition from the medical com-
munity of the applicability, effectiveness, and practicality
of catheter-based transcatheter valve therapies has further
increased interest in these treatments. Training program
content, standards, credentialing, and board certiﬁcations
for cardiac surgical procedures and percutaneous coronary
intervention are well developed, but there is no such
structure in the ﬁeld of percutaneous structural or valvular
heart disease therapies. The purpose of this article is to
outline criteria for operator and institutional require-
ments, to enable institutions and providers to participate
responsibly in this new and rapidly developing ﬁeld.
The emergence of transcatheter valve repair and
implantation has been facilitated by innovative devices,
rapidly developing techniques, and careful patient selec-
tion. The combination of interventional skills, equipment,
collaborative clinical management, surgical approaches,
techniques, and decision-making distinguish the qual-
iﬁcations to participate in this ﬁeld as unique, as does the
complexity of the patients requiring these therapies (2,3).
Given both the high-risk nature of these catheter inter-
ventions and the availability of established alternative
treatment options using traditional surgical approaches,
several considerations are important for institutions and
operators planning to implement these new technologies.
Deﬁning operator and institutional requirements for
these novel therapies is an important ﬁrst step to ensur-
ing their optimal implementation.
Establishing a structural heart disease intervention
therapy program requires several key components
(Table I). The deﬁning principle is that this effort is a joint,
institutionally based activity for cardiologists and cardiacCollege of Cardiology (www.cardiosource.org), and the Society of Thoracic
Surgeons (www.sts.org). For copies of this document, please contact
Elsevier Inc. Reprint Department, fax 212-462-1935, or e-mail reprints@
elsevier.com.
Permissions: Multiple copies, modiﬁcation, alteration, enhancement, and/or
distribution of this document are not permitted without the express permission
of the American College of Cardiology. Requests may be completed online via
the Elsevier site (http://www.elsevier.com/authors/obtaining-permission-to-re-
use-elseviermaterial).
TABLE I Mitral Valve Institutional and Operator Requirements
Institutional 1,000 Cath/400 PCI per Yeara
Interventionalist 50 Structural procedures per year (including ASD/PFO and trans-septal punctures)
Suitable training on devices to be used
Surgical program 25 Total mitral valve procedures per year, of which at least 10 must be mitral valve repairsb
All cases must be submitted to a single national database
Existing programs 15 Mitral (total experience)
Ongoing CME (or nursing/technologist equivalent) of 10 h per year of relevant material
All cases must be submitted to a single national database
New programs Because the indications are not deﬁned, no volume criteria can be proposed yet
Assuming approval would be for high-risk cohorts, 10%–15% mortality rate at 30 days, similar to registry or published data
65% 1-year survival rate
Ongoing CME (or nursing/technologist equivalent) of 10 h per year of relevant material
All cases must be submitted to a single national database
Training Operator must be board certiﬁed in interventional cardiology or board certiﬁed/board eligible in pediatric cardiology or similar
boards from outside the United States. Cardiac surgeons must be board certiﬁed in thoracic surgery, or similar foreign equivalent.
aWith acceptable outcomes for conventional procedures compared to NCDR benchmarks. bMitral valve procedures should be those done for severe mitral regurgitation. Mitral valve
procedures for mild or moderate mitral regurgitation done at the time of other cardiac surgical procedures (AVR, CABG) do not meet this criterion.
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1517surgeons (4). Thus, the specialty that provides some of
these components will vary from program to program.
A transcatheter valve therapy program that uses only
one specialty is fundamentally deﬁcient, and valve ther-
apy programs should not be established without this
multidisciplinary partnership. Comprehensive multi-
disciplinary teams (MDT) are, therefore, required for
transcatheter valve therapies and structural interven-
tional programs.
KNOWLEDGE BASE AND SKILLS
The critical cornerstone of a transcatheter valve program
is a formal, collaborative effort between interventional
cardiologists and cardiac surgeons. This element is
essential to establishing a transcatheter valve program.
No one individual, group, or specialty possesses all the
necessary skills for the best patient outcomes (5). The
overarching goal of these programs must be to provide the
best possible patient-centered care (6).
Since these are new techniques, the correlation
between operator experience and performance metrics for
these procedures has yet to be established. The current
pool of trained individuals is composed predominantly of
those who have participated in industry-sponsored trials
aimed at device approval. Therefore, the translation of
currently available experiences with transcatheter valve
therapies to the “real world” has yet to be evaluated in the
United States.
Several core concepts should be implemented for all
physicians performing these procedures, irrespective of
their specialty background (7,8). They should all possess
extensive knowledge of valvular heart disease, including
the natural history of the disease, hemodynamics,
appropriate diagnostics, optimal medical therapy, the
application and outcome of invasive therapies, and pro-
cedural and perioperative care (9).The ability to interpret echocardiographic and other
radiographic images (obtained at baseline, during the
procedure and follow-up) is critical. Procedural echo
guidance is critical to the procedural success and the
procedural echocardiographer must be highly skilled.
MDTs and procedural teams need to possess skills to
acquire and interpret transthoracic and transesophageal
studies. The use of 3D echocardiography is essential.
Expertise in the interpretation of CT scans of the ilio-
femoral vessels, cardiac anatomy, as well as aortic, mitral,
and pulmonary valvular anatomy is critical for deter-
mining patient eligibility and the best approach and type
of invasive procedure (10,11).
As noted, there is as yet no demonstrated direct corre-
lation between operator experience with speciﬁc pro-
cedures and the skills necessary to perform transcatheter
valve procedures. Furthermore, the speciﬁc skills required
for each procedure are different. There are, however, some
core concepts that professional societies have accepted as
important for both facilities and operators (12,13). Mini-
mum training for speciﬁc procedures and devices will,
for the immediate future, be primarily dictated by FDA
approval requirements. Simulation should play a signiﬁ-
cant role in technical training and proﬁciencymaintenance
for these evolving procedures (14–18). As the procedures
become integrated into mainstream care delivery, the
strategy for training will likely need to be revised.
Minimum requirements for transcatheter valve thera-
pies include an understanding of basic radiation safety
necessary for optimal imaging, operator and patient
exposure protection, and knowledge of the use of X-ray
contrast agents, which may not be standard in cardiac
surgery training and experience.
Training in the use of closed systems for hemody-
namic monitoring and contrast injections will result in
optimal integration into catheterization laboratories and
hybrid environments. Catheter and wire skills, including
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equipment available to access complex anatomy and
negotiate vascular and anatomic structures, are required.
Understanding of the interplay of wires, catheters, and
anatomy is required for completion of these procedures.
These skills can be acquired in a variety of ways. Prior
experience with a variety of interventional techniques is
important. These include but are not limited to:
n Coronary diagnostic procedures
n Coronary interventions
n Peripheral vascular diagnostic procedures
n Peripheral vascular interventions
n Balloon aortic, mitral and pulmonic dilatation
n Stent implantation in right ventricle outﬂow tract and
pulmonary arteries
n IABP and other cardiac support device placement,
including initiation of percutaneous cardiopulmonary
bypass
n pVAD placement
n EVAR or TEVAR procedures
n Transseptal techniques
n Coronary sinus access
n Large vessel access and closure.
The experience of an interventionalist or surgeon
should be relevant to the transcatheter valve procedure
undertaken. For example, primary valve experience with
aortic valve replacement should not be considered ade-
quate experience for the performance of transcatheter
mitral valve repair, because skill sets for one valve type
do not necessarily translate to another valve type.
The application of sterile techniques, consistent with
operating rooms standards, must be applied to these
procedures and team members.
As one of the leaders of the team performing these
procedures, the interventionalist must be able to enforce
compliance with these standards. These procedures may
involve open or partially open surgical components.
Operating theater standards for sterile technique are
therefore mandatory to ensure optimal patient outcomes.
FACILITIES
The institution should have an active valvular heart dis-
ease surgical program with at least two institutionally
based cardiac surgeons experienced in valvular surgery,
and should contain a full range of diagnostic imaging and
therapeutic facilities, including:
1. Cardiac catheterization laboratory or hybrid operating
room/cath lab equipped with a ﬁxed radiographic
imaging system with ﬂat-panel ﬂuoroscopy offering
catheterization laboratory-quality imaging. A bi-plane
unit may be advantageous, particularly for congenital
heart disease.2. Non-invasive imaging
a. Echocardiographic laboratory. Transthoracic and
transesophageal echocardiographic capabilities with
sonographers and echocardiographers experienced
in valvular heart disease. Access to 3D echo-
cardiography is necessary.
b. Vascular laboratory (non-invasive) with vascular
specialists capable of performing and interpreting
vascular studies.
c. CT laboratory with CT technologists and specialists
who can acquire and interpret cardiac CT studies.
3. Physical space—The implantation suite must have a
sterile environment that meets operating room stand-
ards. Furthermore, it must have sufﬁcient space to
accommodate the necessary equipment for uncompli-
cated implantations as well as any additional equip-
ment that may be necessary in the event of
complications. Space for anesthesiology, echocardiog-
raphy, and cardiopulmonary bypass equipment and
personnel is essential. A speciﬁcally designed hybrid
OR interventional suite is ideal; however, in the
absence of such a facility, the interventional cardiac
suite should have:
a. Circulating HVAC laminar ﬂow diffusers (providing
smooth, undisturbed air ﬂow and usually placed
directly over the procedure table) to meet air
requirements for surgery rooms.
b. Asymmetrical/symmetrical 6-lamp 2  4 troffers
(the inverted, usually metal trough suspended from
the ceiling as a ﬁxture for ﬂuorescent lighting) to
provide adequate high-output lighting for surgical
interventions.
c. An adequate number of power receptacles that meet
surgical equipment requirements.
d. For existing mitral valve procedures, cardiopulmo-
nary bypass is almost never needed, but the room
will likely be used for multiple types of structural
procedures and with evolving techniques CPB may
be more frequently necessary, thus adequate space
to run the CPB machine in the interventional suite is
desirable.
e. Gas outlets for the anesthesia machine.
f. An adequate room size to accommodate the standard
equipment required in a cardiac catheterization lab-
oratory (e.g., HD displays and monitors, O2 analyzer,
deﬁbrillator/resuscitation cart, O2 supply, suction,
compressed air, CO-oximeter, ACT analyzer)
4. Minimum room size of 800 square feet (74.3 m2)
to accommodate echocardiographic equipment, sonog-
raphers, anesthesia equipment, the emergency CT sur-
gical team, and cardiopulmonary bypass equipment
(e.g., surgeon, assistant, scrub tech, pump techs), if
needed. Although inmitral cases, the need for emergent
cardio-pulmonary bypass is minimal, the expectation is
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and the ability to convert to an OR is appropriate.
5. Equipment—The interventional suite should stock
a large variety of interchangeable equipment, including
various access kits, endovascular sheaths, and intro-
ducers ranging from 4-F to 26-F in various lengths, a
wide range of guide wires for various purposes, cardiac
diagnostic and interventional catheters, vascular clo-
sure devices, balloon dilatation catheters ranging from
2 mm to 30 mm in diameter and of various lengths
and proﬁles, bare metal and covered stents (coronary
and peripheral), occlusive vascular devices, snares and
other retrieval devices, drainage catheters, and various
implantable device sizes with their delivery systems.
6. Post-procedure intensive care facility with personnel
experienced in managing patients who have under-
gone conventional open-heart valve procedures.
7. Use of a mobile C-arm imaging system in an operating
room is not adequate.
8. HYBRID OR—The Cath Lab Standards Document has
outlined the speciﬁcations for a hybrid Cath Lab (19).
Most importantly, there must be dedication on the part
of the hospital to provide these services and support, both
ﬁnancially and with no time constraints on the personnel
involved. A dedicated administrator as a member of the
team is necessary.OTHER INSTITUTIONAL RESOURCES–FACILITIES,
EQUIPMENT (DISPOSABLES AND CAPITAL
EQUIPMENT), PERSONNEL, SUPPORT, AND
COMMITMENT
For pre- and post-procedure care and joint formal multi-
disciplinary patient consultation, adequate outpatient
clinical care facilities are necessary. Appropriate ofﬁce
space for the medical, nursing, and technical personnel
involved is also required, preferably in a central setting.
Ancillary testing facilities (pulmonary function, echo-
cardiography, vascular duplex scanning, clinical labo-
ratory, MSCT) should be of high quality and be able to
accommodate the patient load in a timely manner.
By their very nature, these complex procedures should
only be performed in institutions that currently and rou-
tinely carry out relatively high volumes of surgical aortic,
pulmonic, tricuspid, and mitral valve operations with
established and veriﬁable track records of optimal surgi-
cal and interventional cardiology outcomes. Similarly,
only institutions with interventional cardiology programs
that have established and successful track records with
balloon aortic and mitral valvuloplasty, catheter closure
of periprosthetic valvular leaks, trans-septal procedures,
insertion of atrial or ventricular septal closure devices,
etc., should develop an integrated structural heart MDT.The institutional commitment required for a successful
program goes beyond the necessary space, personnel, and
specialized facilities set forth above. The complex and
time-consuming pre-procedure patient triage process
and the amount and intensity of post-procedure patient
care after discharge are labor intensive for the physicians,
advanced practitioners (NP and PA), and nursing staff, as
are informed consent and communication with patients,
families, and referring providers. Heart Team decision-
making conferences are valuable to patient care; there-
fore, future reimbursement models should take these
conferences into consideration when developing policy.
In addition to supporting the core nursing and technical
support staff, arrangements between the institution and
the physicians need to be in place to cover physician
efforts dedicated to non-reimbursable hours of clinical
care and medical management of the program.
The complexity of transcatheter valve procedures and
the magnitude of institutional resources required are
similar to established heart transplant and cardiac assist
device programs, for which dedicated professionals, a
minimum of infrastructure, a multidisciplinary team, RN/
NP/PA, providers, coordinators, databases, and quality
reporting are essential for optimal patient outcomes. This
concept was endorsed by the Centers for Medicare and
Medicaid Services through the establishment of certiﬁ-
cation criteria for the use of heart transplantation and
cardiac assist devices in centers and, moreover, for eligi-
bility for reimbursement of services provided. The same
regulatory system was applied to professionals providing
these services. Transcatheter valve treatment programs
should undergo a similar regulatory process with CMS
endorsement. Centers should be approved for speciﬁc
transcatheter valve programs (aortic, mitral, and/or pul-
monic) based on a minimum number of cases per year,
and perioperative and 1-year outcomes above a minimum
threshold.
Long-term outcome reporting is obligatory in order
to track not only survival, but also parameters including
periprocedural complications (e.g., CVA, vascular, renal,
infectious), mitral regurgitation (MR), the need for inter-
vention, subsequent surgery, and quality of life. This type
of reporting is essential because long-term outcome goals
for these new procedures have not been established at
this early stage. Development of a national data registry
and participation by all institutions are mandatory.
MULTIDISCIPLINARY TEAM
The use of a team approach has been shown to improve
outcomes in these types of complex procedures (20). The
MDT necessary for an interventional valve therapy pro-
gram involves far more than just a collaboration between
the interventional cardiologist and cardiac surgeon. In
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extend to various departments are necessary. The idea
that the MDT is composed of individual physicians
working in a room performing the procedures is a super-
ﬁcial view that does not take into account the level of
resources necessary for a successful valve therapy pro-
gram. The interaction among specialists in the MDT is
fundamental, particularly for pre-procedure patient
evaluation and selection. While there is great excitement
about the application of transcatheter valve therapies,
most of these therapies will only be indicated for a small
portion of the population for the immediate future.
Proper decision-making and determination of best
options for any given patient require an evaluation by the
MDT (21).
On-site valve surgery is an essential component of any
valve therapy program. The requirement for on-site valve
surgery is based not only on the potential need for
emergency or “back-up” surgery for percutaneous
patients, but more importantly on the quality of patient
evaluation and selection, decision-making, intra-proce-
dure management, and post-procedure care and
outcomes.
A cardiac surgeon and an interventional cardiologist
must evaluate every case. The interplay between inter-
ventional cardiologists and cardiac surgeons represents
only part of the beneﬁt of the MDT. Additional critical
contributions are provided by cardiac anesthesiology,
imaging specialists in both cardiology and radiology, and
by the many people beyond the physician members of
the team. The MDT is led by a core group of physicians
from interventional cardiology, cardiac surgery, cardiac
anesthesiology, and intensive care and cardiac imaging
departments, along with congenital heart disease spe-
cialists and surgeons. Depending on the institutional
organization and the needs of the patient, vascular sur-
gery and interventional radiology departments will also
participate in the MDT in many situations. Additional
team members include nurse practitioners from all of
these ﬁelds, data/research coordinators, and a dedicated
administrator.
The function of the MDT is essential in pre-procedure
patient selection, intra-procedure management and
problem solving, post-procedure management, post-
discharge follow-up, and outcome studies. During proce-
dures, emergencies or unanticipated needs may arise as a
matter of course, even in the most straightforward sit-
uation; this is a familiar situation for proceduralists in any
ﬁeld. The rapid availability of the MDT support to help
with decision-making or with therapy is essential. A clear
deﬁnition of roles for the various specialties as well as
effective communication, which may be different from
that for conventional procedures, is critical for successful
outcomes. A difﬁcult course post-procedure is common inthe high-risk patients who comprise a large part of the
target population for both transcatheter and operative
valve therapies. A team approach to problem solving in
this setting is critical. Another important part of patient
management is the familiarity that the intensive care unit
and the monitored step-down ﬂoor staff have with the
speciﬁc details of each form of valve therapy. After the
post-procedure management phase, long-term follow-up
for this select group of patients is also part of the MDT’s
responsibility. Post-approval registries will be required
for many of the new transcatheter valve therapies, and
therefore, a data collection/research unit within the MDT
is another required component.
For sites with no prior trial experience in mitral,
transcatheter therapies, background experience with
related procedures is important. Surgical mitral proce-
dures and trans-septal puncture procedures are essential
background elements necessary for mitral therapy pro-
grams. For transcatheter procedures that do not directly
involve the surgeon as a procedure operator, the role of
the cardiac surgeon remains critically important. The
surgeon has many roles and is often a patient advocate
and/or referring physician, may be the primary operator
and is a necessary scientiﬁc study participant in all of
these device applications. The surgeon is familiar with
established standards of care for application of trans-
catheter therapies and is frequently in charge of assessing
high-risk patients for catheter-based therapy as an alter-
native to surgery. In a valve therapy program, patient
assessment is a multidisciplinary undertaking.
Another mechanism for promoting a team approach
that involves both surgeons and cardiologists is split or
shared physician reimbursement for these procedures,
which this writing group strongly endorses. This impor-
tant principle will ensure that surgeons and cardiologists
participate jointly in performing procedures and that
each patient receives the best and most patient-centered
treatment.
The MDT should meet formally as a group on a regular
basis (aside from the usual “cath conference”) to review
all patients referred for procedures, the performance of
recent procedures (to discuss both good and poor out-
comes), and follow-ups of prior procedures.
FUNCTION OF THE MULTIDISCIPLINARY TEAM
Programmatic success depends on the ability of the
MDT to function effectively in the best interest of a given
patient. To do so, the MDT must work cohesively through
the processes of patient selection, procedural planning,
procedural conduct, periprocedural care, and longitudinal
follow-up. Through each phase of this continuum, the
individual skills of the MDT members should be brought
to bear upon the process.
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begins with patient selection. Given the complexity of the
decision-making process surrounding these procedures,
all MDT members must provide objective input and
judgments from the outset of a patient evaluation. The
patient selection process may be initiated by the use of
regularly scheduled patient selection conferences atten-
ded by all MDT members. Such conferences are analogous
to transplant patient selection committee meetings, and
they provide a venue in which patient-speciﬁc data and
imaging are formally presented and discussed by the
MDT. The respective expertise of each discipline repre-
sented among MDT members may then be synthesized
into a patient-speciﬁc recommendation. Each member
of the heart team that evaluates the patient must record
his/her opinion and enter it formally into the patient
record.
Direct patient evaluation by cardiologists and cardiac
surgeons may be accomplished jointly and, if possible,
simultaneously in a venue such as a multi-disciplinary
valve program clinic. Not only does such a clinic provide
convenience for many patients, but it also provides an
opportunity for cardiac surgeons and cardiologists to
jointly examine and evaluate complex cases.
In so doing, the expertise and judgment of both dis-
ciplines may be woven into a patient-speciﬁc decision.
The participation of anesthesiologists in these clinics may
also be useful.
Following the decision that a given patient is an
appropriate candidate for transcatheter mitral valve
therapy, the procedure must then be carefully planned.
Cardiac surgical teams are familiar with, and routinely use
the concept of, “pre-procedure brieﬁngs,” prior to com-
plex cardiac surgical operations. This should be applied to
structural procedures as well. In such brieﬁngs, all team
members (surgeons, interventionalists, anesthesiologists,
perfusionists, nurses, technicians, etc.) discuss the
intended procedure, including the steps of the planned
procedure, the speciﬁc tools and equipment needed
(beyond those typically used), the possible complications
that may arise during the course of the procedure, and the
contingency plans that will be implemented should the
unexpected occur. All members of the team can then
initiate the planned procedure with a common under-
standing of its conduct and what will happen if the plan
needs to change.
Adding the cardiologist and the catheterization team to
this pre-procedure planning and MDT brieﬁng is impor-
tant for procedural success. During the procedure, emer-
gency situations and unexpected needs may arise. The
immediate availability of MDT physician support in
emergency decision-making and therapy is essential. It is
therefore important that the roles of the various special-
ties be clearly delineated during pre-procedure planning.In many cases, the initial post-procedure care should
be provided in an intensive care setting. A team approach
to the care of these patients, and to problem solving, is
important and should include physicians skilled in critical
care medicine. Once inpatients are able to leave the
intensive care environment, they should be attended by a
unit specializing in the care of patients with cardiac dis-
eases, and this unit should be equipped with telemetry-
monitored beds. Again, a team approach is important for
success. The team of physicians, nurses, occupational
and physical therapists, and other members must have an
understanding of the pathophysiology of mitral valve
disease as well as the nuances of care for patients who
have undergone cardiac surgery and interventional car-
diology procedures.
The procedural success of transcatheter valve thera-
pies, including the mitral valve, must be determined via
longitudinal outcomes. Long-term follow-up of these
patients is an important element of the MDT approach.
Post-FDA approval registries will be required for most
transcatheter valve therapies. Therefore, a long-term
relationship between the patient and the MDT must be
established, to undertake the needed alterations in med-
ical therapy, serial echocardiographic imaging, and mon-
itoring of devices. Likewise, changes in patient functional
status, heart failure class, potential device-related com-
plications, and other such conditions must be carefully
tracked. A valve program clinic can provide a venue for
this type of long-term follow-up.
The post-market surveillance of transcatheter valve
devices will be an extremely important function of the
MDT. Participation in device-speciﬁc registries can be
challenging and requires an institutional infrastructure
and commitment that includes experienced data manag-
ers with a background in cardiac disease, funding,
ofﬁce space, and computer resources. It requires a data
coordinating/clinical research unit with rigorous atten-
tion to detail, and the collection of accurate data as an
integral part of the MDT.
CRITERIA FOR ESTABLISHING A TRANSCATHETER
VALVE PROGRAM AND MAINTENANCE OF
COMPETENCE
An important issue in the establishment of a transcatheter
mitral valve program is the clinical or referral base to
ensure an adequate number of patients to provide for the
viability of a program. Table I details the important
requirements for the establishment of a successful
transcatheter mitral valve program.
The surgical program numbers in Table I were obtained
by querying the STS database, which revealed that at the
operative numbers noted, there would be approximately
256 sites in 46 states that would qualify.
Tommaso et al. J A C C V O L . 6 4 , N O . 1 4 , 2 0 1 4
Percutaneous Mitral Valve Procedures O C T O B E R 7 , 2 0 1 4 : 1 5 1 5 – 2 6
1522Once chosen for participation as transcatheter mitral
programs, either as existing programs or as new pro-
grams, in order to maintain ongoing approval for partic-
ipation, sites will need to be monitored to ensure that
they continue to satisfy both the volume and outcome
criteria as described in Table I.
Unlike the signiﬁcant existing experience with PCI,
where abundant data attest to the relationship between
the volume of procedures and outcomes, there are little or
no data on which to draw conclusions as to the volume–
outcome relationship for transcatheter valve therapy.
Therefore, the above recommendations are constructed
to: 1) ensure patient safety, 2) demonstrate that there is a
commitment on the part of the institution to the struc-
tural heart disease program, and 3) use existing volume as
a surrogate for an established valve program to ensure
adequate patient volumes for the establishment of a
sustainable transcatheter valve program. As experience
grows and more data become available, these recom-
mendations will undoubtedly be reﬁned.
TRANSCATHETER MITRAL VALVE REPAIR
MR is a common lesion present in up to 24% of adults with
valvular heart disease (21). It is clear from the literature
that valve repair yields superior outcomes to replacement
in patients with degenerative disease, although the ben-
eﬁts of repair over replacement in patients with func-
tional MR due to ischemic heart disease or dilated
cardiomyopathy are less clear. Due to a combination of
the mitral valve’s structural complexity, unique anatomic
location, and wide variability of pathology, numerous
surgical techniques have been developed over the past
several decades to repair and replace this valve. It is
therefore not surprising that several innovative concepts
for transcatheter mitral valve therapy have been
explored. These transcatheter approaches can be loosely
grouped, based on the anatomic region targeted for
intervention, e.g., leaﬂet repairs, annular repairs, chordal
repairs, and valve implants.
To date, the greatest clinical experience is with leaﬂet
repairs, namely, percutaneous, edge-to-edge coaptation,
in which the anterior and posterior leaﬂets of the mitral
valve are approximated to create a double oriﬁce mitral
valve and restore coaptation. This approach is based on
the surgical technique described by Alﬁeri et al. and has
been used for a variety of pathologic MR disease states
(22,23). By far the greatest transcatheter experience to
date has been with the MitraClip (Abbott Vascular, Santa
Clara, California), the clinical results of which were pub-
lished in the EVEREST I and II trials and the continued
access REALISM registry (23–25). Intraprocedural patient
management requires the participation of the interven-
tional cardiologist, echocardiographer, anesthesiologist,and supporting cardiac surgeon. Other transcatheter
procedures focusing on leaﬂet modiﬁcation (such as
leaﬂet ablation and space occupation between leaﬂets) or
annular reduction are in various stages of development
and are not yet in clinical practice outside of clinical trials
(26–29). It is likely that these procedures will require
similar pre-procedural assessment, intra-procedural per-
sonnel and equipment, operator experience, and post-
procedural assessment and care.
The pre-, intra-, and post-procedure evaluation of MR
patients is arguably the most complex evaluation of the
various valve lesions amenable to any formof transcatheter
therapy. Success will therefore heavily depend on a multi-
disciplinary approach that includes the echocardiographer,
clinical cardiologist, cardiac surgeon, and interventional
cardiologist. Variations on other techniques for trans-
catheter mitral repair are under development and will be
addressed in a future version of these recommendations.
The MitraClip is currently the only mitral valve proce-
dure approved by the FDA. In regards to this procedure,
the collaboration of the cardiothoracic surgeon and
interventional cardiologist will span the pre-, intra-, and
post-procedure care of the patient. The procedure itself is
commonly performed by a single physician. This physician
may be either an interventional cardiologist or a car-
diothoracic surgeon; however, for some patients, the
expertise of two physicians (either two interventional
cardiologists, or an interventional cardiologist and a car-
diothoracic surgeon) could be required. For future trans-
catheter mitral valve replacement, as with TAVR, the
cardiothoracic surgeon and interventional cardiologist are
to be fully involved in all aspects of care: pre-operative
assessment/patient selection, intra-procedural and post-
procedural management and follow-up. Depending on the
nature of subsequently approved devices, intraprocedural
management may require the simultaneous involvement
of an interventional cardiologist and a cardiovascular
surgeon.
NATIONAL REGISTRY
FDA clearance of a novel valve repair or replacement
prosthesis does not guarantee that the device will con-
tinue to demonstrate long-term efﬁcacy equal to cur-
rently available options, or that it will be limited to the
initially approved patient subsets. Post-market studies
organized through individual institutions or multicenter
study groups and registries managed by industry and
professional societies are essential to ensuring continued
short-term safety, and to determining long-term efﬁcacy.
Only with such data can we consider the application of
new valve prostheses to a wider patient population out-
side the boundaries of the study groups examined during
FDA trials. Centers that incorporate transcatheter-based
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the TVT-NCDR database. Early post-procedure morbidity
and mortality analyses, while important for initial and
continued implant safety assessment, are not sufﬁcient to
evaluate the efﬁcacy of valve repair or replacement
prostheses. Studies on long-term follow-up survival and,
more importantly, structural valve degeneration, and the
need for reintervention, are essential.
Transcatheter valve repair or replacement devices are
unique in that an understanding not only of early risk,
but also of long-term durability, is essential to deter-
mining the appropriate patient subgroups for thesetherapies. In our opinion, it is the responsibility of pro-
fessional societies to ensure adequate long-term data
monitoring and to provide oversight and guidance to
industry on the expectations for continued monitoring
beyond the FDA approval phase of device development
and implementation. Individual centers are also respon-
sible for critically evaluating their own experience,
through local and regional quality improvement ini-
tiatives, and for participating in national databases and
registries that facilitate continued safety and efﬁcacy in
the assessment of novel and as yet unproven therapeutic
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